相似文献
1
A FRESH approach: Combining basic science and social good.
Sci Immunol. 2018 Sep 14;3(27). doi: 10.1126/sciimmunol.aau2798.
2
Tackling HIV by empowering adolescent girls and young women: a multisectoral, government led campaign in South Africa.
BMJ. 2018 Dec 7;363:k4585. doi: 10.1136/bmj.k4585.
3
Empowering sex workers? Critical reflections on peer-led risk-reduction workshops in Soweto, South Africa.
Glob Health Action. 2019;12(1):1522149. doi: 10.1080/16549716.2018.1522149.
4
Peer education, gender and the development of critical consciousness: participatory HIV prevention by South African youth.
Soc Sci Med. 2002 Jul;55(2):331-45. doi: 10.1016/s0277-9536(01)00289-1.
5
Peer led HIV/AIDS prevention for women in South African informal settlements.
Health Care Women Int. 2003 Jul;24(6):502-12. doi: 10.1080/07399330303975.
6
Addressing adolescents' risk and protective factors related to risky behaviours: Findings from a school-based peer-education evaluation in the Western Cape.
SAHARA J. 2016 Dec;13(1):197-207. doi: 10.1080/17290376.2016.1241188.
7
Poverty alleviation = good medicine.
S Afr Med J. 2003 Apr;93(4):240-1.
8
The impact of social environments on the effectiveness of youth HIV prevention: a South African case study.
AIDS Care. 2005 May;17(4):471-8. doi: 10.1080/09540120412331319705.
9
Who are the peer educators? HIV prevention in South African schools.
Health Educ Res. 2011 Jun;26(3):563-71. doi: 10.1093/her/cyq064. Epub 2010 Nov 15.
10
'I think condoms are good but, aai, I hate those things': condom use among adolescents and young people in a Southern African township.
Soc Sci Med. 2001 Jun;52(11):1613-27. doi: 10.1016/s0277-9536(00)00272-0.
引用本文的文献
1
Slow virologic control but strong immune and metabolic recovery with dolutegravir-anchored therapy in an HIV cohort in Ghana.
Virol J. 2025 Jul 19;22(1):247. doi: 10.1186/s12985-025-02873-w.
2
Antiretroviral therapy initiated during acute infection in women with HIV-1 clade C reduces anti-Tat antibody production and lowers CD8+ T cell activation.
Front Immunol. 2025 Jun 18;16:1564960. doi: 10.3389/fimmu.2025.1564960. eCollection 2025.
3
Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies.
PLoS Pathog. 2025 Jun 23;21(6):e1013245. doi: 10.1371/journal.ppat.1013245. eCollection 2025 Jun.
4
Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
J Virol. 2025 Jun 17;99(6):e0000825. doi: 10.1128/jvi.00008-25. Epub 2025 May 16.
5
Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial.
Lancet Microbe. 2025 Apr 3:101037. doi: 10.1016/j.lanmic.2024.101037.
6
The utility of nonhuman primate models for understanding acute HIV-1 infection.
Curr Opin HIV AIDS. 2025 May 1;20(3):218-227. doi: 10.1097/COH.0000000000000920. Epub 2025 Mar 27.
7
Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection.
Elife. 2025 Feb 20;13:RP96617. doi: 10.7554/eLife.96617.
8
Standard of prevention for infectious diseases' prevention clinical trials during pandemics: learning lessons for global policies from biomedical HIV prevention clinical trials and a case study of COVID-19.
Front Public Health. 2025 Jan 21;12:1539840. doi: 10.3389/fpubh.2024.1539840. eCollection 2024.
9
'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.
HIV Res Clin Pract. 2025 Dec;26(1):2455917. doi: 10.1080/25787489.2025.2455917. Epub 2025 Jan 25.
10
Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal.
J Virus Erad. 2024 Dec 13;10(4):100575. doi: 10.1016/j.jve.2024.100575. eCollection 2024 Dec.
本文引用的文献
1
Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study.
Lancet HIV. 2018 Jan;5(1):e35-e44. doi: 10.1016/S2352-3018(17)30146-7. Epub 2017 Oct 1.
2
Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women.
Immunity. 2017 Jan 17;46(1):29-37. doi: 10.1016/j.immuni.2016.12.013. Epub 2017 Jan 10.
3
Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.
Lancet Infect Dis. 2016 Apr;16(4):441-8. doi: 10.1016/S1473-3099(15)00429-6. Epub 2015 Dec 24.
4
Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point.
Immunity. 2015 Sep 15;43(3):591-604. doi: 10.1016/j.immuni.2015.08.012. Epub 2015 Sep 8.
5
Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract.
Immunity. 2015 May 19;42(5):965-76. doi: 10.1016/j.immuni.2015.04.019.
Zotero 插件